David S. Grayzel
Independent DirectorDr. David S. Grayzel, also known as Dave, M.D., is Director of Trace Neuroscience, Inc. Dr. Grayzelis Co-Founder and Chair of Vima Therapeutics, Inc. Dr. Grayzel is Director of Comanche Biopharma Corp. since January 17, 2024. He had been an Independent Director of Aerovate Therapeutics, Inc. since August 6, 2020. Dr. Grayzel is on the Scientific Advisory Board of the Tri-TDI that includes Rockefeller University. Dr. Grayzel served as an Independent Director of Surface Oncology, Inc. until September 08, 2023 and served as its Director since April 2014. He has been Independent Director of Affinia Therapeutics, Inc. since March 2020. He serves as Director of Caesura Therapeutics, ANP Therapeutics and Q23 Bio. He served as Vice President of Clinical Development and Medical Affairs at Infinity Pharmaceuticals, Inc since August 2002 until June 2010. He serves as a Director of Triana Biomedicines, Inc. He serves as Director at Acera School, Inc. (The Massachusetts School for Science, Creativity and Leadership). Dr. Grayzel also serves as an advisor to Memorial Sloan Kettering Cancer Center’s Technology Development Fund and a scientific advisory board member of the Tri-Institutional Therapeutics Discovery Institute. He serves as Board Observer at Day One Biopharmaceuticals, Inc. He served as President and Treasurer at Q32 Bio Inc. and also serves as its Independent Director since 2017. He served as Director at Xilio Development, Inc. (formerly known as Xilio Therapeutics, Inc.) since January 2018 until 2021. He is a Partner at Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). since 2014. Dr. Grayzel is a part of the life sciences group. He focuses on investments in novel therapeutics often those that are near to first in human clinical testing. He is board member of TRIANA Biomedicines. He joined Atlas in 2010 as Managing Director of Atlas Venture Development to lead innovative, “built-to-buy“ asset-centric initiative that partners with pharma and biotech companies to develop preclinical and clinical stage programs through to key value inflection points. Dr. Grayzel joined Atlas Venture during its start-up phase, where he established its clinical capabilities to run trials from phase 1 through global phase 3 registration studies. His responsibilities also included clinical strategy, clinical development, operations, pharmaco-vigilance and medical affairs, as well as co-chairing the Scientific Leadership Team. In addition, he shared responsibility for the creation and implementation of the overall corporate and business strategy which included going public in 2006 and establishing major corporate alliances with Medimmune/AZ and Purdue PharmaHe served as the Chairman of board of directors at Q32 Bio, Inc until December 2020. He serves as a Board Member of Akrevia Therapeutics. He is a Director of Acera. He is a Co-Founder and acting Chief Executive Officer of Cadent Therapeutics. He is also a Co-Founder of Quartet Medicine. Dr. Grayzel served as Chief Executive Officer of Surface Oncology, Inc since April 2014 until May 2015. He led Infinity Pharmaceutical's (NASDAQ: INFI) clinical research efforts as the head of clinical development and medical affairs. Dr. Grayzel co-founded and served as Chief Executive Officer of Arteaus Therapeutics, LLC from June 2011 until it was acquired by Eli Lilly and Company in January 2014 and served as co-founder and Chief Executive Officer of Annovation Biopharma, Inc. from May 2011 until it was acquired by The Medicines Company in February 2015. Dr. Grayzel served as Director of Corporate Development and Senior Medical Director of Infinity Pharmaceuticals, Inc. He joined Infinity Pharmaceuticals, Inc. from Dyax Corp. He was a member of the executive team at Infinity Pharmaceuticals and was responsible for all clinical research activities as the head of clinical development and medical affairs, as well as co-chairing the company's scientific leadership team. In addition, as a member of the executive team, he shared responsibility for the creation and implementation of the overall corporate and business strategy that included going public in 2006 and establishing major corporate alliances with J&J, Amgen, Novartis, Medimmune/AZ and Purdue Pharma. At Dyax Corp., he served as Director of Corporate Development and Business Operations, responsible for marketing and commercialization strategy for therapeutic products in the development pipeline, including late-stage clinical trials as well as business initiatives for in-licensing of targets, out-licensing of late-stage compounds and co-development partnerships. He served as Curriculum Director at Stanford University Medical Center, where he created its first case-based medical ethics curriculum. He held a variety of positions in clinical research as well as both corporate and business development. He worked at Harvard Medical School in the Department of Genetics investigating familial inheritance of cardiovascular disease and assisted in identifying the gene causing Holt-Oram Syndrome. He served as Executive Chairman of Surface Oncology, Inc. since April 2014 until January 4, 2017. He has been a Director of Cadent Therapeutics since March 2014. He was a founding board member of Delinia since September 2015 until January 2017. He served as a Director at Arteaus Therapeutics, LLC. He holds a B.A. with honors in Psychology from Stanford University. Dr. Grayzel obtained MD from Harvard Medical School. He completed his Internship and Residency Training in Internal Medicine at Massachusetts General Hospital.
Positions
- Company NameQ32 Bio Inc.Stock CodeQTTBPositionIndependent DirectorColleagues
- JPJodie Pope MorrisonCEO & Director
- MTMark T. IwickiIndependent Chairman of the Board
- LHLee H. KalowskiCFO & President
- SMShelia M. VioletteCo-founder, Chief Scientific Officer & President of Research
- DADavid AppuglieseSenior VP & Head of People
- MMMaria MarzilliChief Business Officer
- KDKathleen D. LaPorteIndependent Director
- MTMary T. ThistleIndependent Director
